Statistically significant improvements in respiratory symptoms were seen in both adult and pediatric patients

Improvements were substantially smaller in adult patients but still statistically significant. Two weeks after completion of treatment, a difference in respiratory symptoms between treatment groups was still present, though the difference was smaller.

Click here to review full study design

Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

Improvements in FEV1 were comparable across adult and pediatric patients on Day 28 of treatment4

Adult/pediatric FEV1 lung function chart

Two weeks after completion of drug treatment, the difference in FEV1 between CAYSTON and placebo groups continued but decreased to 6% (95% CI: 2%, 9%).